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ABSTRACT
Adjuvant arthritis (AA) is a frequently used model of experimental arthritis. Because of its histo-
pathology, which is reminiscent of rheumatoid arthritis in humans, AA is used as a model for the
development of novel anti-inflammatory drugs. Recently, it has become evident thatAA is a typical
T-cell-mediated autoimmune condition. Therefore, novel immunotherapies targeted to T cells can
be developed in this model. Analysis of responding T cells in AA have now led to the definition of
various antigens with potential relevance to arthritis, including human arthritic conditions. One
such antigen defined inAA is the 60kD heat shock protein. Both T-cell vaccination approaches and
active antigen immunizations and antigen toleration approaches have turned out to be effective in
suppressing AA. Infect. Dis. Obstet. Gynecol. 7:49-54, 1999. (C) 1999 Wiley-Liss, Inc.
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n adjuvant arthritis (AA), disease is induced by
substances that have no obvious antigenic rela-
tionships with joint tissues. Originally this experi-
mental model was discovered by Pearson when
he observed the development of arthritis in rats
after experimental immunizations using complete
Freund’s adjuvant containing heat-killed mycobac-
teria. Proof of the role of T cells was obtained by
Holoshitz et al. when they were able to select an
arthritogenic T-cell line from cells obtained from
mycobacteria-immunized Lewis rats.
Upon cellular cloning, several CD4+ T-helper
subclones were obtained. One of these subclones
was found to be virulently arthritogenic. This par-
ticular subclone was found to proliferate not only in
the presence of mycobacterial antigens, but also in
the presence of semi-purified preparations of car-
tilage proteoglycans, e These findings led to the
concept of molecular mimicry between a mycobac-
terial antigen and a cartilage-associated self-antigen
as the critical pathogenic mechanism explaining
mycobacteria-induced arthritis.
Later the mycobacterial antigen was defined as
the mycobacterial heat shock protein (hsp) 60, and
the epitope of the arthritogenic T cell turned out to
be nonconserved with a limited sequence homol-
ogy with a rat proteoglycan link-protein sequence.
Although supportive evidence for the relevance of
this homology was obtained, for instance in human
T-cell responses, it is uncertain whether this link-
protein sequence is the target structure in AA.
Recently, the unique relationship of the 180-
188 sequence with the arthritic process was further
substantiated by tolerating rats for this particular
sequence by administering this peptide in the nose
(nasal tolerance) or by giving it subcutaneously in
phosphate-buffered saline at high dosages (high
dose tolerance). This procedure was seen to pro-
tect the animals from the subsequent induction
of arthritis by either mycobacteria in oil or by
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the nonantigenic synthetic adjuvant avridine
(CP20961).
3 Apparently, this single bacterial epi-
tope, which resembles a (so far not identified) self
epitope at the site of inflammation, is capable of
inducing regulatory mechanisms of peripheral tol-
erance. The success of this regimen in suppressing
disease, and especially in the case of nonmicrobi-
ally induced disease, seems to support the possi-
bility that this microbial epitope has a unique re-
lationship with a disease critical self-antigen in the
joint. Apparently, the exposition of such antigen at
the mucosal surface of the nose is already sufficient
for setting reactive T cells in a regulatory mode
with the capacity to enforce peripheral tolerance,
leading to disease resistance.
CONSERVED HEAT SHOCK PROTEIN 60
EPITOPES INDUCE ARTHRITIS SUPPRESSIVE
T CELLS
The identification of mycobacterial hsp60 as a criti-
cal antigen in arthritis has led to many studies on
the potential of hsp60 in modifying arthritis devel-
opment. Immunization experiments in mice and
rats using hsp60 proteins or their derivative pep-
tides have never led to induction of arthritis. On
the contrary, resistance to arthritis was seen to de-
velop. Prior immunization of experimental animals
with mycobacterial hsp60 has been found to pro-
tect against subsequent induction of AA,4 strepto-
coccal cell wall arthritis,s avridine (a non-antigenic
lipoidal amine) arthritis in rats,6 and also pristane7
and collagen arthritis8 in mice. Careful analyses of
differential T-cell responsiveness of whole myco-
bacteria- (AA induction protocol) versus mycobac-
terial hsp60- (protection protocol) immunized rats
have now pointed out that the arthritis inductive
capacity of whole mycobacteria does coincide with
dominant responses directed to the mimicry epi-
tope 180-188.9 This is not the case when the hsp60
protein is used for immunization. Cellular cloning
of responsive T cells in the latter protective proto-
col has revealed clones that recognize sequences
conserved between mycobacterial and mammalian
hsp60. Adoptive transfer experiments have shown
that such T cells, recognizing conserved sequences
and in particular the mycobacterial 256-265 se-
quence, were capable of transferring protection
against the disease.1 Furthermore, it was demon-
strated that such cells had the capacity of respond-
ing to heat-shocked spleen cells. Immunizations
with conserved peptide 256-265 were also induc-
ing arthritis protection, and none of several other
peptides containing nonconserved dominant T-cell
epitopes tested was capable of inducing any pro-
tection. Testing of the same 256-265 peptide in a
very different arthritis model in Lewis rats, in this
case avridine arthritis, revealed that in a nonbacte-
rially induced model the protective potential of the
peptide was also present. Protection was also found
using the homologous rat (self) peptide. Recent
experiments have shown similar protective effects
to result from immunization with mycobacterial
hspT0 both in AA and avridine arthritis. Also, for
the smaller subunit of the hsp60 complex (GroES
of Escherichia coli of 10kD molecular weight), ar-
thritis protective potential has been documented.
SUPPRESSION IN ARTHRITIS MODELS IS
SPECIFIC FOR HEAT SHOCK PROTEINS
Given the observation that conserved epitopes of
hsps induced resistance to arthritis by setting a fo-
cus of T-cell reactivity directed to recognition of
self homolog (human) hsp, one could easily ask
whether other conserved bacterial proteins would
have similar arthritis protective capacities. How-
ever, in striking contrast with the protection in au-
toimmune disease models obtained with hsps, such
as hsp60, hspT0, and hspl0, we have seen recently
that a set of other conserved, but not stress induc-
ible, bacterial proteins, such as superoxide dismu-
tase, glyceraldehyde-3-phosphate-dehydrogenase,
and aldolase, did not protect in experimental ar-
thritis, despite their good immunogenicity and se-
quence homologies with their mammalian ho-
mologs (Prakken et al., submitted). Therefore, it
seems that the protective quality of hsps is a
unique aspect of hsps, possibly caused by their ex-
quisite behavior of upregulating local expression
under conditions of stress such as that existing at
sites of inflammation.
HEAT SHOCK PROTEINS IN AUTOIMMUNE
AND OTHER INFLAMMATORY DISEASES
Despite the frequent occurrence of hsp antibodies
in normal individuals, it seems that in the majority
of inflammatory diseases raised levels of hsp anti-
bodies can be found. 11 This has been reported
for rheumatoid arthritis (RA), juvenile RA (JRA),
reactive arthritis, Behcet disease, systemic lupus
erythematosus (SLE), Crohn Disease, insulin-
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dependent diabetes mellitus (IDDM), and mul-
tiple sclerosis (MS). Significant hsp-specific T-cell
responses have been observed in RA, JRA (see be-
low), Behcet disease, MS, and in graft infiltrating
lymphocytes during transplant rejection episodes.
Raised expression of hsps in diseased tissues has
been documented in sarcoidosis, SLE, inflamma-
tory liver diseases, chronic gastritis (gastric ulcer),
celiac disease, MS, IDDM, and atherosclerosis.
Despite the general perception that hsps seem to
play a role in different autoimmune di’seases, there
is no consensus on cause-and-effect relationships.
Evidence in favor of hsps being a trigger leading to
autoimmunity, because of their conserved nature,
is hardly available. A more plausible possibility is
that inflammation in general causes raised tissue
expression, leading to the generation of hsp-
specific T- and B-cell responses.
Similar to what has been documented in many
other autoimmune conditions, rheumatic diseases
have also been seen to feature the sequelae of im-
mune responses to hsps. This is most evident from
serology studies that have shown the presence of
raised levels of hsp60-specific antibodies in pa-
tients. Raised expression of hsp in inflamed tissues
has been documented for arthritic synovium in
both RA and JRA.
lz In children, this raised expres-
sion has been seen to be an event that occurred
early in the development of disease. Despite ear-
lier reports also claiming prominent T-cell re-
sponses to mycobacterial hsp60 in advanced RA,
more recent studies have suggested that prolifera-
tive T-cell responses are, however, more confined
to early RA and that in advanced RA, such re-
sponses are less prominent. Alternatively, re-
sponses have been detected in functional assays
sensitive for cytokine production, such as in assays
measuring the effect of mononuclear cells on car-
tilage proteoglycan turnover in vitro. 1" In reactive
arthritis and in oligoarticular juvenile rheumatoid
arthritis (OA-JRA), T-cell responses to hsp60 were
again more prominent. In contrast to adult RA,
these conditions are characterized by a remitting
course of disease development. 14,1s
In adult RA patients, T-cell responses to human
hsp60 were detectable by culturing the cells in the
presence of added interleukin (IL) 4. Bacterial
hsp60 was found to stimulate cells without added
IL4. This suggests a Th2 nature of the T cells
responding to the human molecule in particular. 16
In children with OA-JRA, responses to human
hsp60 coincided with raised expression of IL4 in
the synovial cells (as determined by reverse tran-
scription-polymerase chain reaction). Further-
more, stimulation of both synovial and peripheral
blood T cells resulted in a raised CD30 expression
(a possible marker for Th2 cells) in activated
(CD45RO+) CD4+ and CD8+ T cells. In addition
OA-JRA patient-derived hsp60-specific T-cell
lines were shown to produce IL4 and transforming
growth factor-13 (TGF-I3).s
Altogether the data obtained from human arthri-
tis patients have shown the potential of hsps to
trigger the release of Th2-associated and suppres-
sive cytokines.
HEAT SHOCK PROTEINS ARE AN
INTRINSIC COMPONENT OF THE
SLOW-ACTING ANTIRHEUMATIC
DRUG OM89
In various models of experimental autoimmunity,
it is known that exposing animals to exogenous
bacterial flora contributes to resistance against dis-
ease induction. In AA also, germ-free animals were
more susceptible than their conventionally reared
counterparts. 17 Furthermore, in Fisher rats, it was
shown that the susceptible germ-free animals be-
came resistant upon gut recolonization with E. coli
bacteria.
In other words, exposure of the immune system
to cross-reactive bacterial antigens, such as hsps,
might well stimulate the immune system to resume
control over unwanted self-reactive clones. In line
with the known contribution of bacterial gut flora
to tolerance, it seems best to effectuate such expo-
sure through oral (or nasal)administration of bac-
terial antigens. Laboratoires-OM (Geneva, Switzer-
land) is producing a glycoprotcin rich extract of E.
coli (OM-89), which is marketed and used as a
slow-acting drug for the treatment of RA. It is ad-
ministered orally and has shown a therapeutic ef-
ficacy comparable with that of gold in trials in RA
patients. Recent analyses have revealed that E. coli
hsp60 (GroEL) and hsp70 (DnaK) are the domi-
nant immunogens present in this material. s,19 Fur-
thermore, both in AA and in avridine arthritis in
Lewis rats, OM-89 was found to protect against
arthritis. Therefore, E. coli hsps, when adminis-
tered orally, may trigger a T-cell regulatory event
that contributes to the control of RA in a way simi-
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lar to the effect of mycobacterial hsp60 in models
of arthritis. It is therefore possible that the thera-
peutic potential of hsps in RA is already exempli-
fied to some extent by the mode of action of
OM-89.
MECHANISMS BY WHICH HEAT SHOCK
PROTEINS PRODUCE PROTECTION IN
AUTOIMMUNE ARTHRITIS
The early expression of hsp60 in inflamed synovial
tissues (stress-response) and the findings of immu-
nological recognition of the protein both at the
level of antibodies and T cells, especially in remit-
ting arthritic diseases, seem to tie in very well with
the data obtained in the experimental animal mod-
els. The animal experiments have shown that, ir-
respective of’the trigger that led to synovial inflam-
mation, prior stimulation of immunity to self-hsp60
using bacterial hsp60 or its conserved peptide
raised resistance to subsequent disease induction.
Taken together, these findings have indicated that
T-cell recognition of hsp60 (and also hspl0 and
hsp70) at the site of inflammation does contribute
to the control of the ongoing inflammatory re-
sponse. The stimulation of such responses by prior
immunization using bacterial hsp or its relevant
peptides is therefore expected to facilitate such T-
Cell-mediated regulatory control.
Heat-shock proteins are, despite their conserved
nature and therefore antigenic relationship with
"self," immunogenic to an exceptionally high de-
gree. Although the reasons for this are as yet un-
clear, this phenomenon can be understood in terms
of repertoire selection.
Heat shock proteins are well expressed in the
thymic medulla, at the sites where positive thymic
selection occurs. This will lead to selection of a
repertoire ofT cells that have a receptor that allows
low-affinity (antagonistic) interactions with self-
hsp when it becomes overexpressed at sites of in-
flammation. High-affinity receptors were nega-
tively selected and therefore deleted. During in-
fection with an hsp expressing microorganism (any
bacterium, parasite, etc.), the same repertoire will
be expanded by recognition of the microbial hsp
homolog. As the homolog will be antigenically
close to the self-hsp, but not identical to it, this
recognition will include high-affinity interactions.
By their nature, these high-affinity interactions
may lead to an aggressive (Thl) anti-infectious re-
sponse. At the same time, this repertoire is numeri-
cally expanded. On re-encounter of these T cells
with self-hsp as expressed in the inflammatory site,
the interaction will again be of low affinity and lead
to antagonistic T-cell regulation. In other words,
exposure of the immune system to microbial hsps
is expanding a repertoire of potentially anti-
inflammatory T cells. The same repertoire expan-
sion can be effectuated by directed stimulation the
immune system with hsps or peptides thereof.
Given the existing evidence that responses to hsps
comply with peripheral tolerance mechanisms of
immune deviation, it is likely that bystander sup-
pressive mechanisms (secretion of IL4, TGF-[3)
are operational in hsp-induced anti-inflammatory
mechanisms.
On the other hand, it may be that under normal
conditions low-level expression of self-hsp epit-
opes by nonprofessional antigen presenting cells in
the periphery or of conserved microbial hsp epit-
opes in the ’tolerating’ gut environment is continu-
ously noted by T cells. This recognition, however,
in the absence of costimulation or in the otherwise
tolerating mode, will drive such T cells into a regu-
latory phenotype or anergy. Upon subsequent in-
volvement of such cells in autoimmune inflamma-
tion, they will exert regulatory activity, also when
they recognize their overcxpressed antigen pre-
sented by the professional antigen presenting cells.
Recently, we demonstrated that anergic T cells
suppressed, in coculture, proliferative responses of
other T cells as soon as the antigen that was used
to induce anergy was added to the coculture,z In
the case of hsps, thus anergised cells could focus
their regulatory activity to sites of inflammation
where hsps become temporarily overexpressed
(bystander suppression). In infection, the activity
of such anergic regulators would be outweighed
by a dominant frequency of T cells (vigorously)
responding to nonconserved microbial hsp epit-
opes. Depending on the circumstances, the pro-
inflammatory response will (temporarily) break pe-
ripheral tolerance. And indeed, upon immunization
or infection, microbe-specific epitopes are more
dominantly recognized. The hsp-induced protec-
tion against autoimmune inflammation is now ex-
plained by either the expansion of the self-hsp
cross-reactive T cells that assume the ancrgic phe-
notype when encountering their antigen on non-
professional antigen presenting cells, or by further
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imprinting or spreading of the preexistent anergic
state.
LESSONS FOR THE DEVELOPMENT OF
SPECIFIC IMMUNOTHERAPY
IN AUTOIMMUNITY
As argued above, immunity to bacterial antigens,
such as hsps, may contribute to maintenance of self
tolerance as a hedge against autoimmunity. To
achieve a lasting restoration of such tolerance in the
case of disease, it seems most adequate to target
immunotherapy to the reinforcement of natural
mechanisms that contribute to such maintenance
of self-tolerance. In other words, exposure of the
immune system to bacterial antigens, such as hsps,
might well stimulate the immune to resume control
over unwanted self-reactive clones. In line with the
known contribution of bacterial gut flora to toler-
ance, it seems best to effectuate such exposure
through oral administration of bacterial antigens.
Although little support for the effectiveness of such
an approach can be obtained from work in experi-
mental disease models, so far from experience in
human medicine such support can be obtained. As
mentioned above, Laboratories-OM has been pro-
ducing E. coli bacterial lysates containing bacterial
hsps, which are used among others for the treat-
ment of RA. el For obvious reasons, it would be of
great interest to analyze such mechanisms at the
level of T-cell responses in patients treated with
this material.
Positive findings of such an analysis would then
possibly lead to attempts to develop better defined
pharmaceutical compounds, such as synthetic pep-
tides. Such peptides could be composed of con-
served sequences of bacterial hsps and be used to
stimulate the frequency or activity of T cells with
the potential to recognize self-hsp molecules, ex-
pressed at sites of inflammation.
On a limited scale, first experience with oral
administration of a defined hsp peptide has been
obtained by Albani.zz Based on the sequence ho-
mology of an E. coli dnaJ sequence with the so-
called "shared-epitope," a consensus sequence
shared by RA-associated HLA-DR molecules, the
peptide QKRAA was administered to RA patients
in an open-label clinical trial. Upon analysis of the
functional phenotype of responding T cells in
these patients, it appears that the oral treatment
did effectuate a relative shift from Thl to Th2 in
cells with specificity for the dnaJ peptide.
The manipulation of peripheral tolerance with
hsp immunization may work through the reinforc-
ing of natural protective mechanisms of T-cell
regulatory events in inflammation. The approach is
broad and can be useful for the treatment of in-
flammation as seen in various autoimmune diseases
and other inflammatory diseases, such as allergy.
Furthermore, spin-off treatments may be expected
for infection (including vaccines) and cancer. The
ubiquitous nature of hsp expression in diseased tis-
sues may well ensure that antigenic spreading as a
possible tolerance escape mechanism will not eas-
ily take place. This is in contrast to alternative,
more conventional antigen-specific approaches.
Effective treatment leading to reduced hsp ex-
pression in the tissues will lead to a gradual loss of
therapeutic impact as a useful built-in feedback
mechanism, or, in other words no therapeutic over-
shoot.
In the exploration of mechanisms of peripheral
tolerance, it has become evident that, besides con-
trol through specific elimination of cells, interac-
tive regulatory effects of antigens do play a role.
Work on antagonistic peptides, anergic T cells, and
cells displaying a regulatory cytokine profile has
provided an experimental basis for such effects.
Heat shock proteins can be the example of how
such interactive regulatory effects can be targeted
to sites of cellular stress. Immunological recogni-
tion of hsps, as seen in association with virtually
every inflammatory condition, including allograft
rejection and autoimmune diseases, can be central
to peripheral tolerance mechanisms meant to con-
trol inflammation beyond tissue-specific antigenic
manipulation,zz
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